How infectious SARS-CoV-2 exploits two ER membrane proteins to promote infection

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5R01AI170514-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2027
  • Known Financial Commitments (USD)

    $381,807
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Billy Tsai
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF MICHIGAN AT ANN ARBOR
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Abstract SARS-CoV-2 exploits the function of the endoplasmic reticulum (ER) to promote its infection life cycle. Despite its strong reliance on the ER, the molecular basis by which SARS-CoV-2 hijacks ER factors to promote defined steps of this life cycle remains unclear. Using infectious SARS-CoV-2, we recently identified two ER membrane proteins - RTN3 and SigmaR1 - as critical host factors that support virus infection. Our findings further reveal that RTN3 plays a role in viral replication, while SigmaR1 exerts a function in viral secretion. However, how SARS-CoV-2 exploits the activities of RTN3 and SigmaR1 to accomplish these two distinct tasks, in mechanistic terms, is completely unknown. Accordingly, the objective of this application is to elucidate the molecular basis by which these two ER membrane factors promote replication and secretion of SARS- CoV-2. We believe these insights will not only illuminate the basic infection mechanism of SARS-CoV-2, but given the continuing global COVID-19 pandemic, may lead to the development of effective anti-virals to blunt the devastating impact of SARS-CoV-2.